FDA grants emergency authorisation to Lilly’s COVID-19 antibody
Bamlanivimab approved for high-risk COVID-19 patients
Read More
Tag: Bamlanivimab
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
